Skip to main content
SpringerLink
Log in

Follow-Up for Testicular Cancer

  • Living reference work entry
  • First Online:
Urologic Oncology

  • 137 Accesses

Abstract

There are some specifics in testis cancer patients compared to other tumor entities. The excellent cure rates, even in advanced tumor disease, the young age, and the broad-spectrum of treatment options including reduction in treatment intensity lead to a long life expectancy with different rates of tumor relapse and side effects. Follow-up in testis cancer is worthwhile; cure rates are high even in relapsed disease. Follow-up should be frequent enough to detect relapse and side effects early enough to treat it and seldom enough to be feasible and not to harm patients, e.g., by exposure against ionizing radiation.

Therefore, anamnesis, clinical examination, different imaging procedures, and blood test should be done. Follow-up schedules are adapted to histology, clinical stage, and treatment modalities. Additionally, personalization of follow-up for some patients is essential, especially due to the broad-spectrum of side effect. In the vast majority of testicular cancer patients, a follow-up for 5–10 years and above is needful.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Abouassaly R, Fosså SD, Giwercman A, Kollmannsberger C, Motzer RJ, Schmoll HJ, Sternberg CN. Sequelae of treatment in long-term survivors of testis cancer. Eur Urol. 2011;60:516–26.

    Article  Google Scholar 

  • Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C, Schulze H, Heidenreich A, de Riese W, Loy V, Bierhoff E, Wittekind C, Fimmers R, Hartmann M, German Testicular Cancer Study Group. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol. 2003;21(8):1505–12.

    Google Scholar 

  • Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Wessbach L, Loy V, Wittekind C, Hartmann M. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol. 2008;26(18):2966–72.

    Article  CAS  Google Scholar 

  • Albers P, et al. Maligne Hodentumoren. In: Rübben H, editor. Uroonkologie. Berlin/Heidelberg: Springer; 2014.

    Google Scholar 

  • Aparicio J, Maroto P, del Muro XG, Gumà J, Sánchez-Muñoz A, Margelí M, Doménech M, Bastús R, Fernández A, López-Brea M, Terrassa J, Meana A, del Prado PM, Sastre J, Satrústegui JJ, Gironés R, Robert L, Germà JR. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol. 2011;29(35): 4677–81. https://doi.org/10.1200/JCO.2011.36.0503.

    Article  Google Scholar 

  • Bokemeyer C, Nowak P, Haupt A, Metzner B, Köhne H, Hartmann JT, Kanz L, Schmoll HJ. Treatment of brain metastasis in patients with testicular cancer. J Clin Oncol. 1997;15:1449–54.

    Article  CAS  Google Scholar 

  • Buchler T, Kubankova P, Boublikova L, et al. Detection of second malignancies during long-term follow-up of testicular cancer survivors. Cancer. 2011;117(18): 4212–8.

    Article  Google Scholar 

  • Cathomas R, Hartmann M, Krege S, Souchon R, Lorch A, Mayer F, De Santis M, Gillessen S. Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. Onkologie. 2011;34:59–64.

    Article  Google Scholar 

  • Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R, Weinknecht S, Köhrmann U, Bamberger M. Radiotherapy for stage IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol. 2003;21(6):1101–6.

    Article  Google Scholar 

  • Classen J, Souchon R, Hehr T, Hartmann M, Hartmann JT, Bamberg M. Posttreatment surveillance after paraaortic radiotherapy for stage I seminoma: a systematic analysis. J Cancer Res Clin Oncol. 2010;136(2):227–32.

    Article  Google Scholar 

  • Cost NG, Adibi M, Lubahn JD, Romman A, Raj GV, Sagalowski AI, Margulis V. Effect of testicular germ cell tumor therapy on renal function. Urology. 2012; 80(3):641–8.

    Article  Google Scholar 

  • De Felice F, Musio D, Gravina GL, Marampon F, Tombolini V. Adjuvant radiation therapy in stage I seminoma: 20 years of oncologic results. Oncotarget. 2016;7(48):80077–82. https://doi.org/10.18632/oncotarget.11374.

  • De La Pena H, Sharma A, Glicksman C, Joseph J, Subesinghe M, Traill Z, Verrill C, Sullivan M, Redgwell J, Bataillard E, Pintus E, Dallas N, Gogbashian A, Tuthill M, Protheroe A, Hall M. No longer any role for routine follow-up chest X-rays in men with stage I germ cell cancer. Eur J Cancer. 2017;84:354–9.

    Google Scholar 

  • De Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fosså SD, Cook P, de Prijck L, Stenning S, Collette L. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001; 19(6):1629–40.

    Google Scholar 

  • Dieckmann KP, Classen J, Loy V. Diagnosis and management of testicular intraepithelial neoplasia (carcinoma in situ) – surgical aspects. APMIS. 2003;111(1):64–8.

    Article  Google Scholar 

  • Dieckmann KP, Albers P, Classen J, De Wit M, Pichlmeier U, Rick O, Müllerleile U, Kuczyk M. Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol. 2005;173(3):824–9.

    Article  Google Scholar 

  • Dieckmann KP, Anheuser P, Sattler F, Von Kügelgen T, Matthies C, Ruf C. Sequential bilateral testicular tumours presenting with intervals of 20 years and more. BMC Urol. 2013;13:71. https://doi.org/10.1186/1471-2490-13-71.

  • Dieckmann KP, Dralle-Filiz I, Matthies C, Heinzelbecker J, Bedke J, Ellinger J, Anheuser P, Souchon R, Pichlmeier U, German Testicular Cancer Study Group. Testicular seminoma clinical stage 1: treatment outcome on a routine care level. J Cancer Res Clin Oncol. 2016;142(7):1599–607. https://doi.org/10.1007/s00432-016-2162-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dieckmann KP, Radtke A, Spiekermann M, Balks T, Matthies C, Becker P, Ruf C, Oing C, Oechsle K, Bokemeyer C, Hammel J, Melchior S, Wosniok W, Belge G. Serum levels of microRNA miR-371a-3p: a sensitive and specific new biomarker for germ cell tumours. Eur Urol. 2017;71(2):213–20. https://doi.org/10.1016/j.eururo.2016.07.029.

    Article  CAS  PubMed  Google Scholar 

  • EAU Guidelines on Testicular cancer (2018) Presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1.

    Google Scholar 

  • Flechon A, Culine S, Theodore C, Droz J-P. Pattern of relapse after first line treatment of advanced stage germ-cell tumors. Eur Urol. 2005;48:957–64.

    Article  CAS  Google Scholar 

  • Fosså SD. Long-term sequelae after cancer therapy – survivorship after treatment for testicular cancer. Acta Oncol. 2004;43:134–41.

    Article  Google Scholar 

  • Gerl A, Clemm C, Schmeller N, Hartenstein R, Lamerz R, Willmanns W. Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer. 1995;72:1026–32.

    Article  CAS  Google Scholar 

  • Gerl A, Barba M, Weiss M, Liedl B, Zimmermann F, Clemm C. Hodentumoren. Manual Urogenitale Tumoren. Tumorzentrum München u. Zuckschwerdt, München (article in german). 2003.

    Google Scholar 

  • Gilligan T. Testicular cancer survivorship. Hematol Oncol Clin North Am. 2011;25:627–39.

    Article  Google Scholar 

  • Hartmann M, Krege S, Souchon R, De Santis M, Gillessen S, Cathomas R. Nachsorge von Hodentumoren. Interdisziplinäre evidenzbasierte Empfehlungen. Urologe. 2011;50:830–5.

    Article  CAS  Google Scholar 

  • Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydoy M, Oldenburg J, Dahl AA, Bremnes RM, Fosså SD. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol. 2012;30:3752–63.

    Article  Google Scholar 

  • International Germ Cell Cancer Collaborative Group (IGCCCG). The International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancer. J Clin Oncol. 1997; 15:594–603.

    Article  Google Scholar 

  • Jewett MAS, Grabowski A, McKiernan J. Management of recurrence and follow-up for cancer. Urol Clin N Am. 2003;30:819–30.

    Article  Google Scholar 

  • Krege S, Beyer J, Souchon R, Albers P, Albrecht E, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG). Part I and II. Eur Urol. 2008;53:478–513.

    Article  Google Scholar 

  • Nayan M, Jewett MA, Hosni A, Anson-Cartwright L, Bedard PL, Moore M, Hansen AR, Chung P, Warde P, Sweet J, O’Malley M, Atenafu EG, Hamilton RJ. Conditional risk of relapse in surveillance for clinical stage I testicular cancer. Eur Urol. 2017;71(1):120–7.

    Article  Google Scholar 

  • Nord C, Bjoro T, Ellingsen D, et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol. 2003;44:322–8.

    Article  Google Scholar 

  • Oechsle K, Bokemeyer C, Kollmannsberger C, Mayer F, Berger LA, Oing C, Honecher F. Bone metastases in germ cell tumor patients. J Cancer Res Clin Oncol. 2012;138(6):947–52.

    Article  CAS  Google Scholar 

  • Oldenburg J, Martin J, Fosså SD. Late relapse of germ cell malignancies: incidence, management and prognosis. J Clin Oncol. 2006;24:5508–11.

    Article  Google Scholar 

  • Oliver RTD, Ong J, Shamash J, Ravi R, Nagund V, Harper P, Ostrowski MJ, Sizer B, Levay MJ, Robinson A, Neal DE, Williams M. Long-term follow-up of Anglian Germ Cell Cancer Group: surveillance versus patients with stage I nonseminoma treated with adjuvant chemotherapy. Urology. 2004; 63(3):556–61.

    Article  CAS  Google Scholar 

  • Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Stenning SP. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011;29(8):957–62. https://doi.org/10.1200/JCO.2009.26.4655.

    Article  CAS  PubMed  Google Scholar 

  • Richiardi L, Scelo G, Bofetta B, et al. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer. 2007;120:623–31.

    Article  CAS  Google Scholar 

  • Rustin GJ, Mead GM, Sally P, et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197 – the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol. 2007;10:1310–5.

    Article  Google Scholar 

  • Sohaib SA, Koh DM, Barbachano Y, Parikh J, Husband JE, Dearnaley DP, Horwich A, Huddart R. Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol. 2009;64:362–7.

    Article  CAS  Google Scholar 

  • Souchon R, Hartmann M, Krege S, Lorch A, Mayer F, De Santis M, Gillessen S, Beyer J, Cathomas R. Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients. Strahlenther Onkol. 2011; 187:158–66.

    Article  Google Scholar 

  • Spermon JR, Kiemeney LA, Meulemann EJ, Ramos L, Wetzels AM, Witjes JA. Fertility in men with testicular germ cell tumors. Fertil Steril. 2003;79(Suppl 3): 1543–9.

    Article  Google Scholar 

  • Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stiener U, Sollberg A, Langberg C, Bremnes RM, Laurell A, Wijkstrom H, Klepp O. Risk-adapted treatment in clinical stage I nonseminomatous germ cell cancer: the SWENOTECA management program. J Clin Oncol. 2009;27:2122–8.

    Article  Google Scholar 

  • Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, Laurell A, Stierner UK, Ståhl O, Cavallin-Ståhl EK, Klepp OH, Dahl O, Cohn-Cedermark G. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian Testicular Cancer Study Group. J Clin Oncol. 2011;29(6):719–25. https://doi.org/10.1200/JCO.2010.30.1044.

    Article  PubMed  Google Scholar 

  • Tandstad T, Ståhl O, Dahl O, Haugnes HS, Håkansson U, Karlsdottir Å, Kjellman A, Langberg CW, Laurell A, Oldenburg J, Solberg A, Söderström K, Stierner U, Cavallin-Ståhl E, Wahlqvist R, Wall N, Cohn-Cedermark G, SWENOTECA. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol. 2016;27(7):1299–304.

    Article  CAS  Google Scholar 

  • Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997;89:1429–39.

    Article  CAS  Google Scholar 

  • Travis LB, Fosså SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005;97:1354–65.

    Article  Google Scholar 

  • Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, Constine LS, Oeffinger KC, Okunieff P, Armstrong G, Wiljer D, Miller RC, Gietema JA, van Leeuwen FE, Williams JP, Nichols CR, Einhorn LH, Fosså SD. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst. 2010;102:1114–30.

    Google Scholar 

  • Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von der Maase H. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002; 20:4448–52.

    Google Scholar 

  • Zengerling F, Kunath F, Jensen K, Ruf C, Schmidt S, Spek A. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance – a systematic review. Urol Oncol. 2017. https://doi.org/10.1016/j.urolonc.2017.06.047. pii: S1078-1439(17)30331-9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Federal Armed Forces Hospital, Ulm, Germany

    Christian G. Ruf

Authors
  1. Christian G. Ruf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian G. Ruf .

Editor information

Editors and Affiliations

  1. Urologie, Univ Lübeck, Lübeck, Schleswig-Holstein, Germany

    Axel Merseburger

  2. Dept. of Urology, University of Regensburg St. Josef Medical Centre, Regensburg, Germany

    Maximilian Burger

Section Editor information

  1. Universitätsklinikum Rostock, Urologische Klinik und Poliklinik, Rostock, Germany

    Chris Protzel

  2. Division of Oncological Urology, Department of Urology, University of Köln, Köln, Germany

    Axel Heidenreich

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Ruf, C.G. (2019). Follow-Up for Testicular Cancer. In: Merseburger, A., Burger, M. (eds) Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42603-7_11-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42603-7_11-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42603-7

  • Online ISBN: 978-3-319-42603-7

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation